Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia

08:58 AM EDT, 10/16/2026 (MT Newswires) -- Ascendis Pharma (ASND) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization in the European Union for once-weekly TransCon CNP to treat achondroplasia in children two years and older whose epiphyses are not closed. The pharmaceutical company said the positive opinion is based on a review that included clinical data from three randomized, double-blind, placebo-controlled clinical trials, as well as up to three years of open-label extension data. Ascendis said it expects a final decision from the European Commission in Q4. The company also said that if approved, it expects to launch TransCon CNP under the brand name Yuviwel in Germany in Q1 2027. "With a highly favorable response from the achondroplasia community to its differentiated profile, TransCon CNP remains a foundational product in our growth disorder portfolio, positioned to support our Vision 2030 objectives," President and Chief Executive Jan Mikkelsen said in a statement.